Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion

Chi Un Pae; Hyun Kook Lim; Changsu Han; Ashwin A. Patkar; David C. Steffens; Prakash S. Masand; Chul Lee

doi:10.1586/14737175.7.10.1251

Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion

Chi Un Pae, Hyun Kook Lim, Changsu Han, Ashwin A. Patkar, David C. Steffens, Prakash S. Masand, Chul Lee

Research output: Contribution to journal › Review article › peer-review

64 Citations (Scopus)

Abstract

Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.

Original language	English
Pages (from-to)	1251-1263
Number of pages	13
Journal	Expert Review of Neurotherapeutics
Volume	7
Issue number	10
DOIs	https://doi.org/10.1586/14737175.7.10.1251
Publication status	Published - 2007 Oct
Externally published	Yes

Bibliographical note

Funding Information:
AA Patkar is a consultant for Bristol-Myers Squibb, Glaxo-SmithKline and Reckitt Benckiser; is on the speaker’s bureau of Bristol-Myers Squibb, GlaxoSmithKline and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer.

Funding Information:
C Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant.

Funding Information:
C-U Pae has received research support from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceu-tcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning. He has received honoraria and is on the speaker’s bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceut-cals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc., and Otsuka Korea.

Keywords

Bupropion
Fatigue
Major depressive disorder

ASJC Scopus subject areas

General Neuroscience
Clinical Neurology
Pharmacology (medical)

Access to Document

10.1586/14737175.7.10.1251

Cite this

@article{0f6fc56e27dd48169308e700a76c621c,

title = "Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion",

abstract = "Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.",

keywords = "Bupropion, Fatigue, Major depressive disorder",

author = "Pae, {Chi Un} and Lim, {Hyun Kook} and Changsu Han and Patkar, {Ashwin A.} and Steffens, {David C.} and Masand, {Prakash S.} and Chul Lee",

note = "Funding Information: AA Patkar is a consultant for Bristol-Myers Squibb, Glaxo-SmithKline and Reckitt Benckiser; is on the speaker{\textquoteright}s bureau of Bristol-Myers Squibb, GlaxoSmithKline and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer. Funding Information: C Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant. Funding Information: C-U Pae has received research support from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceu-tcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning. He has received honoraria and is on the speaker{\textquoteright}s bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceut-cals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc., and Otsuka Korea.",

year = "2007",

month = oct,

doi = "10.1586/14737175.7.10.1251",

language = "English",

volume = "7",

pages = "1251--1263",

journal = "Expert Review of Neurotherapeutics",

issn = "1473-7175",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

TY - JOUR

T1 - Fatigue as a core symptom in major depressive disorder

T2 - Overview and the role of bupropion

AU - Pae, Chi Un

AU - Lim, Hyun Kook

AU - Han, Changsu

AU - Patkar, Ashwin A.

AU - Steffens, David C.

AU - Masand, Prakash S.

AU - Lee, Chul

N1 - Funding Information: AA Patkar is a consultant for Bristol-Myers Squibb, Glaxo-SmithKline and Reckitt Benckiser; is on the speaker’s bureau of Bristol-Myers Squibb, GlaxoSmithKline and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer. Funding Information: C Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant. Funding Information: C-U Pae has received research support from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceu-tcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning. He has received honoraria and is on the speaker’s bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceut-cals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc., and Otsuka Korea.

PY - 2007/10

Y1 - 2007/10

N2 - Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.

AB - Fatigue is one of the most common symptoms found in both community and medical care settings. Fatigue may imply a prodromal or residual symptom of major depressive disorder or an adverse reaction to antidepressant treatment. Fatigue may also compromise antidepressant treatment by delaying response to antidepressants. Despite the importance of fatigue as a core depressive symptom, data specific to the effects of fatigue on pharmacological treatment are still lacking. Bupropion is an atypical antidepressant, chemically unrelated to classical agents such as tricyclic antidepressants, selective serotonin reuptake inhibitors and other contemporary antidepressants. With a pharmacological profile that involves neurotransmitter reuptake inhibition, bupropion shares a broad range of biological properties with psychostimulants. The primary action mode of bupropion involves dopaminergic and noradrenergic neurotransmissions rather than serotonergic mechanisms, although its exact pharmacodynamic properties remain uncertain. Hence, it is possible that bupropion may play a role in the treatment of fatigue-related symptoms of major depressive disorder. This paper presents a brief overview of the clinical implications and neurobiology of major depressive disorderrelated fatigue, as well as the pharmacological profile of bupropion and currently available clinical data related to its treatment of fatigue-related symptoms of major depressive disorder.

KW - Bupropion

KW - Fatigue

KW - Major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=35548974838&partnerID=8YFLogxK

U2 - 10.1586/14737175.7.10.1251

DO - 10.1586/14737175.7.10.1251

M3 - Review article

C2 - 17939764

AN - SCOPUS:35548974838

SN - 1473-7175

VL - 7

SP - 1251

EP - 1263

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

IS - 10

ER -

Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this